Hikma reported a strong performance in H1 19, with revenue growth of 8% (at CER), primarily attributable to a better-than-expected performance of Generics (+11%), along with an in line performance of Injectables (+7%) and Branded (+6%). Lower COGS, due to the closure of the Eatonton facility, along with a higher non-operating income, trickled down into higher profitability (at the reported level). Management upgraded its FY 19 guidance on the back of strong results across the portfolio.
14 Aug 2019
Robust performance of generics in H1 19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust performance of generics in H1 19
Hikma Pharmaceuticals Plc (HIK:LON) | 1,806 180.6 0.6% | Mkt Cap: 4,007m
- Published:
14 Aug 2019 -
Author:
Kamla Singh -
Pages:
4
Hikma reported a strong performance in H1 19, with revenue growth of 8% (at CER), primarily attributable to a better-than-expected performance of Generics (+11%), along with an in line performance of Injectables (+7%) and Branded (+6%). Lower COGS, due to the closure of the Eatonton facility, along with a higher non-operating income, trickled down into higher profitability (at the reported level). Management upgraded its FY 19 guidance on the back of strong results across the portfolio.